Compare Kohl's Corporation (KSS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs Twist Bioscience Corp — how do they compare? Kohl's Corporation trades at $18.98 (market cap $2.10B), while Twist Bioscience Corp trades at $123.83 (market cap $7.72B). The key difference: Twist Bioscience Corp is far larger — about 3.7× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.7% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| KSS | TWST | |
|---|---|---|
Market Cap | $2.10B | $7.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $124.88 |
52-Week Low | $11.72 | $24.16 |
Enterprise Value | $8.20B | $7.65B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $18.96, down 0.42% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows low valuation multiples (P/E of 7.77, P/S of 0.14) amid declining revenue, which fell to $16.22B in 2025. Recent Q1 2026 earnings beat expectations, and the company announced a $0.13 dividend for June 2026, alongside leadership changes including a new COO appointment in September 2026.
The outlook is mixed: low valuations and earnings beats offer value, but persistent sales declines and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility. Investors should weigh cost-cutting progress against macroeconomic headwinds in retail.
Twist Bioscience (TWST) trades at $123.76, down 0.9% on the day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, with 2025 revenue at $376.57 million, though the company remains unprofitable with a net income margin of -31.66%. Recent news highlights an upsized $300 million public offering and an analyst upgrade, contributing to positive sentiment.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, negative cash flow, and high valuation ratios pose significant risks. Investors should weigh the growth trajectory against the path to profitability and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
